Double-blind randomized trial of pirfenidone in Chinese idiopathic pulmonary fibrosis patients

Medicine (United States)

Volumn 94, Issue 42, 2015, Pages e1600-

  Huang, Hui ^a   Dai, Hua Ping ^b   Kang, Jian ^c   Chen, Bao Yuan ^d   Sun, Tie Ying ^e   Xu, Zuo Jun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PIRFENIDONE; PLACEBO; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG BIOPSY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; TOTAL LUNG CAPACITY; WALKING; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES;

EID: 84948172449     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001600     Document Type: Article

References (29)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
2. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167-4171.
3. Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9:111-116.
4. Tatler AL, Jenkins G. TGF-beta activation and lung fibrosis. Proc Am Thorac Soc. 2012;9:130-136.
5. Iyer SS, Ramirez AM, Ritzenthaler JD, et al. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2009;296: L37-L45.
6. Kliment CR, Oury TD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med. 2010;49:707-717.
7. Cui Y, Robertson J, Maharaj S, et al. Oxidative stress contributes to the induction and persistence of TGF-beta1 induced pulmonary fibrosis. Int J Biochem Cell Biol. 2011;43:1122-1133.
8. Carter NJ. Pirfenidone: in idiopathic pulmonary fibrosis. Drugs. 2011;71:1721-1732.
9. Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother. 2013;47:361-367.
10. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010;46:473-482.
11. Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull. 2013;36:1525-1527.
12. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159:1061-1069.
13. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-829.
15. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-1769.
16. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192:e3-e19.
17. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-Acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156:1897-1901.
18. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
19. Sugiura H, Ichikawa T, Liu X, et al. N-Acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts. Pulm Pharmacol Ther. 2009;22:487-491.
20. Felton VM, Borok Z, WillisF BC. N-Acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol. 2009;297:L805-L812.
21. Idiopathic Pulmonary Fibrosis Clinical Research Network Martinez FJ, de Andrade JA, et al. . Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093-2101.
22. Ichikado K, Johkoh T, Ikezoe J, et al. Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol. 1997;168:333-338.
23. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107:1431-1437.
24. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19:740-747.
25. King TJ, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092.
26. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. 2005;172:417-422.
27. Cu A, Ye Q, Sarria R, et al. N-Acetylcysteine inhibits TNF-Alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:147-154.
28. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a german tertiary referral center for interstitial lung diseases. Respiration. 2014;88:199-207.
29. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31:375-391.